抗 LAG-3 增强 CD8 T 细胞效应功能。
Anti-LAG-3 boosts CD8 T cell effector function.
发表日期：2024 Aug 08
作者：
Courtney T Kureshi, Michael Dougan, Stephanie K Dougan
来源：
CELL
摘要：
LAG-3是第三个成功靶向癌症治疗的免疫检查点通路。尽管单一疗法无效，但 LAG-3 和 PD-1 阻断的组合可提高晚期黑色素瘤的生存率。在本期《Cell》中，两项小鼠研究和一项人体临床试验提供了有关 LAG-3 在免疫调节中的见解。版权所有 © 2024 Elsevier Inc. 保留所有权利。
LAG-3 is the third immune checkpoint pathway successfully targeted for cancer therapy. Although ineffective as a monotherapy, combination of LAG-3 and PD-1 blockade improves survival from advanced melanoma. In this issue of Cell, two studies in mice and a human clinical trial provide insights on LAG-3 in immune regulation.Copyright © 2024 Elsevier Inc. All rights reserved.